N,N-diethyl-N-[(2-fluoropyridin-4-yl)methyl]amine | 1176209-98-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N,N-diethyl-N-[(2-fluoropyridin-4-yl)methyl]amine
• 英文别名: N-ethyl-N-[(2-fluoropyridin-4-yl)methyl]ethanamine
• CAS: 1176209-98-5
• 化学式: C₁₀H₁₅FN₂
• 分子量: 182.241
• InChiKey: YGOFNTLCCCQTHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-diethyl-N-[(2-fluoropyridin-4-yl)methyl]amine 在 盐酸 、 正丁基锂 、 盐酸羟胺 、 三甲基铝 、 potassium acetate 、 溶剂黄146 、 二异丙胺 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 正己烷 、 正庚烷 、 二氯甲烷 、 水 为溶剂， 反应 61.33h， 生成 N-[[4-(N,N-diethylaminomethyl)-2-fluoropyridin-3-yl]methyl]-6-iodoquinoxaline-2-carboxamide dihydrochloride
  参考文献：
  名称：

  Single Photon Emission Computed Tomography/Positron Emission Tomography Imaging and Targeted Radionuclide Therapy of Melanoma: New Multimodal Fluorinated and Iodinated Radiotracers

  摘要：

  This study reports a series of 14 new iodinated and fluorinated compounds offering both early imaging (I-123, I-124, F-18) and systemic treatment (I-131) of melanoma potentialities. The biodistribution of each I-125-labeled tracer was evaluated in a model of melanoma B16F0 bearing mice, using in vivo serial gamma scintigraphic imaging. Among this series, [I-125]56 emerged as the most promising compound in terms of specific tumoral uptake and in vivo kinetic profile. To validate our multimodality concept, the radiosynthesis of [F-18]56 was then optimized and this radiotracer has been successfully investigated for in vivo PET imaging of melanoma in B16F0- and B16F10-bearing mouse model. The therapeutic efficacy of [I-131]56 was then evaluated in mice bearing subcutaneous B16F0 melanoma, and a significant slow down in tumoral growth was demonstrated. These data support further development of 56 for PET imaging (F-18, I-124) and targeted radionuclide therapy (I-131) of melanoma using a single chemical structure.

  DOI：

  10.1021/jm101574q
• 作为产物：
  描述：

  2-氟异烟酸 在 氯化亚砜 、 硼烷 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 N,N-diethyl-N-[(2-fluoropyridin-4-yl)methyl]amine
  参考文献：
  名称：

  Single Photon Emission Computed Tomography/Positron Emission Tomography Imaging and Targeted Radionuclide Therapy of Melanoma: New Multimodal Fluorinated and Iodinated Radiotracers

  摘要：

  This study reports a series of 14 new iodinated and fluorinated compounds offering both early imaging (I-123, I-124, F-18) and systemic treatment (I-131) of melanoma potentialities. The biodistribution of each I-125-labeled tracer was evaluated in a model of melanoma B16F0 bearing mice, using in vivo serial gamma scintigraphic imaging. Among this series, [I-125]56 emerged as the most promising compound in terms of specific tumoral uptake and in vivo kinetic profile. To validate our multimodality concept, the radiosynthesis of [F-18]56 was then optimized and this radiotracer has been successfully investigated for in vivo PET imaging of melanoma in B16F0- and B16F10-bearing mouse model. The therapeutic efficacy of [I-131]56 was then evaluated in mice bearing subcutaneous B16F0 melanoma, and a significant slow down in tumoral growth was demonstrated. These data support further development of 56 for PET imaging (F-18, I-124) and targeted radionuclide therapy (I-131) of melanoma using a single chemical structure.

  DOI：

  10.1021/jm101574q

文献信息

• LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS
  申请人：Chezal Jean-Michel

  公开号：US20110044899A1

  公开（公告）日：2011-02-24

  A compound of formula (I): in which R 1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C 1 -C 4 )alkyl] 3 group, Ar represents an aryl group or a heteroaryl group, R 9 represents a hydrogen atom, a (C 1 -C 4 ) alkyl group or forms together with the group R 1 —Ar a ring fused with the Ar group, A represents a group of formula (β) or (δ): R 3 and R 4 independently represent a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 ) alkenyl group or a group of formula (y): wherein R 11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO 2 group, a —NR 5 R 6 group, a N + R 5 R 6 R 7 X − group, or a —OSO 2 R 12 group, and their addition salts with pharmaceutically acceptable acids.

  化合物的化学式为(I)：其中R1代表氢原子、可选择标记的卤素、放射性核素或Sn[(C1-C4)烷基]3基团，Ar代表芳基或杂芳基，R9代表氢原子、(C1-C4)烷基或与基团R1-Ar共同形成与Ar基团融合的环，A代表化学式(β)或(δ)的基团：R3和R4分别独立地代表氢原子、(C1-C6)烷基、(C1-C6)烯基或化学式(y)的基团：其中R11代表可选择标记的卤素、放射性核素、可选择取代的芳基或杂芳基，取代基可以是可选择标记的卤素、放射性核素、—NO2基团、—NR5R6基团、N+R5R6R7X−基团或—OSO2R12基团，以及它们与药物可接受的酸形成的加合物。
• US9125937B2
  申请人：——

  公开号：US9125937B2

  公开（公告）日：2015-09-08
• Single Photon Emission Computed Tomography/Positron Emission Tomography Imaging and Targeted Radionuclide Therapy of Melanoma: New Multimodal Fluorinated and Iodinated Radiotracers
  作者：Aurélie Maisonial、Bertrand Kuhnast、Janine Papon、Raphaël Boisgard、Martine Bayle、Aurélien Vidal、Philippe Auzeloux、Latifa Rbah、Mathilde Bonnet-Duquennoy、Elisabeth Miot-Noirault、Marie-Josèphe Galmier、Michèle Borel、Serge Askienazy、Frédéric Dollé、Bertrand Tavitian、Jean-Claude Madelmont、Nicole Moins、Jean-Michel Chezal

  DOI：10.1021/jm101574q

  日期：2011.4.28

  This study reports a series of 14 new iodinated and fluorinated compounds offering both early imaging (I-123, I-124, F-18) and systemic treatment (I-131) of melanoma potentialities. The biodistribution of each I-125-labeled tracer was evaluated in a model of melanoma B16F0 bearing mice, using in vivo serial gamma scintigraphic imaging. Among this series, [I-125]56 emerged as the most promising compound in terms of specific tumoral uptake and in vivo kinetic profile. To validate our multimodality concept, the radiosynthesis of [F-18]56 was then optimized and this radiotracer has been successfully investigated for in vivo PET imaging of melanoma in B16F0- and B16F10-bearing mouse model. The therapeutic efficacy of [I-131]56 was then evaluated in mice bearing subcutaneous B16F0 melanoma, and a significant slow down in tumoral growth was demonstrated. These data support further development of 56 for PET imaging (F-18, I-124) and targeted radionuclide therapy (I-131) of melanoma using a single chemical structure.